Monoclonal Antibody Therapies for High Risk Neuroblastoma

References

• Yoshida S, Kawaguchi H, Sato S, Ueda R, Furukawa K. An anti-GD2 monoclonal antibody enhances apoptotic effects of anti-cancer drugs against small cell lung cancer cells via JNK (c-Jun terminal kinase) activation. Jpn J Cancer Res. 2002;93(7):816–824. doi:10.1111/j.1349-7006.2002.tb01324.x
   PubMedGoogle Scholar
• Kowalczyk A, Gil M, Horwacik I, Odrowaz Z, Kozbor D, Rokita H. The GD2-specific 14G2a monoclonal antibody induces apoptosis and enhances cytotoxicity of chemotherapeutic drugs in IMR-32 human neuroblastoma cells. Cancer Lett. 2009;281(2):171–182. doi:10.1016/j.canlet.2009.02.040
   PubMed Web of Science ®Google Scholar
• Doronin II, Vishnyakova PA, Kholodenko IV, et al. Ganglioside GD2 in reception and transduction of cell death signal in tumor cells. BMC Cancer. 2014;14:295. doi:10.1186/1471-2407-14-295
   PubMed Web of Science ®Google Scholar
• Weiner LM, Surana R, Wang S. Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nat Rev Immunol. 2010;10(5):317–327. doi:10.1038/nri2744
   PubMed Web of Science ®Google Scholar
• Shuptrine CW, Surana R, Weiner LM. Monoclonal antibodies for the treatment of cancer. Semin Cancer Biol. 2012;22(1):3–13. doi:10.1016/j.semcancer.2011.12.009
   PubMed Web of Science ®Google Scholar
• Dickson PV, Hamner JB, Sims TL, et al. Bevacizumab-induced transient remodeling of the vasculature in neuroblastoma xenografts results in improved delivery and efficacy of systemically administered chemotherapy. Clin Cancer Res. 2007;13(13):3942–3950. doi:10.1158/1078-0432.CCR-07-0278
   PubMed Web of Science ®Google Scholar
• Sano R, Krytska K, Larmour CE, et al. An antibody-drug conjugate directed to the ALK receptor demonstrates efficacy in preclinical models of neuroblastoma. Sci Transl Med. 2019;11:483. doi:10.1126/scitranslmed.aau9732
   Web of Science ®Google Scholar
• Brown BS, Patanam T, Mobli K, et al. Etoposide-loaded immunoliposomes as active targeting agents for GD2-positive malignancies. Cancer Biol Ther. 2014;15(7):851–861. doi:10.4161/cbt.28875
   PubMed Web of Science ®Google Scholar
• Tur MK, Sasse S, Stocker M, et al. An anti-GD2 single chain Fv selected by phage display and fused to Pseudomonas exotoxin A develops specific cytotoxic activity against neuroblastoma derived cell lines. Int J Mol Med. 2001;8(5):579–584. doi:10.3892/ijmm.8.5.579
   Web of Science ®Google Scholar
• Kramer K, Kushner BH, Modak S, et al. Compartmental intrathecal radioimmunotherapy: results for treatment for metastatic CNS neuroblastoma. J Neurooncol. 2010;97(3):409–418. doi:10.1007/s11060-009-0038-7
   PubMed Web of Science ®Google Scholar
• Kramer K, Humm JL, Souweidane MM, et al. Phase I study of targeted radioimmunotherapy for leptomeningeal cancers using intra-Ommaya 131-I-3F8. J Clin Oncol. 2007;25(34):5465–5470. doi:10.1200/JCO.2007.11.1807
   PubMed Web of Science ®Google Scholar
• Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252–264. doi:10.1038/nrc3239
   PubMed Web of Science ®Google Scholar
• Hoehner JC, Gestblom C, Hedborg F, Sandstedt B, Olsen L, Pahlman S. A developmental model of neuroblastoma: differentiating stroma-poor tumors’ progress along an extra-adrenal chromaffin lineage. Lab Investig. 1996;75(5):659–675.
   PubMed Web of Science ®Google Scholar
• Maris JM, Hogarty MD, Bagatell R, Cohn SL. Neuroblastoma. Lancet. 2007;369(9579):2106–2120. doi:10.1016/S0140-6736(07)60983-0
   PubMed Web of Science ®Google Scholar
• Matthay KK, Maris JM, Schleiermacher G, et al. Neuroblastoma. Nat Rev Dis Primers. 2016;2:16078. doi:10.1038/nrdp.2016.78
   PubMed Web of Science ®Google Scholar
• Maris JM. The biologic basis for neuroblastoma heterogeneity and risk stratification. Curr Opin Pediatr. 2005;17(1):7–13. doi:10.1097/01.mop.0000150631.60571.89
   PubMed Web of Science ®Google Scholar
• Maris JM. Recent advances in neuroblastoma. N Engl J Med. 2010;362(23):2202–2211. doi:10.1056/NEJMra0804577
   PubMed Web of Science ®Google Scholar
• Schultz LM, Majzner R, Davis KL, Mackall C. New developments in immunotherapy for pediatric solid tumors. Curr Opin Pediatr. 2018;30(1):30–39. doi:10.1097/MOP.0000000000000564
   PubMed Web of Science ®Google Scholar
• Mujoo K, Cheresh DA, Yang HM, Reisfeld RA. Disialoganglioside GD2 on human neuroblastoma cells: target antigen for monoclonal antibody-mediated cytolysis and suppression of tumor growth. Cancer Res. 1987;47(4):1098–1104.
   PubMed Web of Science ®Google Scholar
• Wu ZL, Schwartz E, Seeger R, Ladisch S. Expression of GD2 ganglioside by untreated primary human neuroblastomas. Cancer Res. 1986;46(1):440–443.
   PubMed Web of Science ®Google Scholar
• Cheung NK, Lazarus H, Miraldi FD, et al. Ganglioside GD2 specific monoclonal antibody 3F8: a phase I study in patients with neuroblastoma and malignant melanoma. J Clin Oncol. 1987;5(9):1430–1440. doi:10.1200/JCO.1987.5.9.1430
   PubMed Web of Science ®Google Scholar
• Mujoo K, Kipps TJ, Yang HM, et al. Functional properties and effect on growth suppression of human neuroblastoma tumors by isotype switch variants of monoclonal antiganglioside GD2 antibody 14.18. Cancer Res. 1989;49(11):2857–2861.
   PubMed Web of Science ®Google Scholar
• Murray JL, Cunningham JE, Brewer H, et al. Phase I trial of murine monoclonal antibody 14G2a administered by prolonged intravenous infusion in patients with neuroectodermal tumors. J Clin Oncol. 1994;12(1):184–193. doi:10.1200/JCO.1994.12.1.184
   PubMed Web of Science ®Google Scholar
• Barker E, Mueller BM, Handgretinger R, Herter M, Yu AL, Reisfeld RA. Effect of a chimeric anti-ganglioside GD2 antibody on cell-mediated lysis of human neuroblastoma cells. Cancer Res. 1991;51(1):144–149.
   PubMed Web of Science ®Google Scholar
• Yu AL, Gilman AL, Ozkaynak MF, et al. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med. 2010;363(14):1324–1334. doi:10.1056/NEJMoa0911123
   PubMed Web of Science ®Google Scholar
• Zeng Y, Fest S, Kunert R, et al. Anti-neuroblastoma effect of ch14.18 antibody produced in CHO cells is mediated by NK-cells in mice. Mol Immunol. 2005;42(11):1311–1319. doi:10.1016/j.molimm.2004.12.018
   PubMed Web of Science ®Google Scholar
• Horta ZP, Goldberg JL, Sondel PM. Anti-GD2 mAbs and next-generation mAb-based agents for cancer therapy. Immunotherapy. 2016;8(9):1097–1117. doi:10.2217/imt-2016-0021
   PubMed Web of Science ®Google Scholar
• Alvarez-Rueda N, Leprieur S, Clemenceau B, et al. Binding activities and antitumor properties of a new mouse/human chimeric antibody specific for GD2 ganglioside antigen. Clin Cancer Res. 2007;13(18):5613s–5620s. doi:10.1158/1078-0432.CCR-07-1057
   Web of Science ®Google Scholar
• Nazha B, Inal C, Owonikoko TK. Disialoganglioside GD2 expression in solid tumors and role as a target for cancer therapy. Front Oncol. 2020;10:1000. doi:10.3389/fonc.2020.01000
   PubMed Web of Science ®Google Scholar
• Cheung NK, Saarinen UM, Neely JE, Landmeier B, Donovan D, Coccia PF. Monoclonal antibodies to a glycolipid antigen on human neuroblastoma cells. Cancer Res. 1985;45(6):2642–2649.
   PubMed Web of Science ®Google Scholar
• Lammie G, Cheung N, Gerald W, Rosenblum M, Cordoncardo C. Ganglioside gd(2) expression in the human nervous-system and in neuroblastomas - an immunohistochemical study. Int J Oncol. 1993;3(5):909–915. doi:10.3892/ijo.3.5.909
   PubMed Web of Science ®Google Scholar
• Jin HJ, Nam HY, Bae YK, et al. GD2 expression is closely associated with neuronal differentiation of human umbilical cord blood-derived mesenchymal stem cells. Cell Mol Life Sci. 2010;67(11):1845–1858. doi:10.1007/s00018-010-0292-z
   Web of Science ®Google Scholar
• Martinez C, Hofmann TJ, Marino R, Dominici M, Horwitz EM. Human bone marrow mesenchymal stromal cells express the neural ganglioside GD2: a novel surface marker for the identification of MSCs. Blood. 2007;109(10):4245–4248. doi:10.1182/blood-2006-08-039347
   PubMed Web of Science ®Google Scholar
• Suzuki M, Cheung NK. Disialoganglioside GD2 as a therapeutic target for human diseases. Expert Opin Ther Targets. 2015;1–14.
   Web of Science ®Google Scholar
• Cavdarli S, Groux-Degroote S, Delannoy P. Gangliosides: the double-edge sword of neuro-ectodermal derived tumors. Biomolecules. 2019;9(8):311. doi:10.3390/biom9080311
   Web of Science ®Google Scholar
• Navid F, Santana VM, Barfield RC. Anti-GD2 antibody therapy for GD2-expressing tumors. Curr Cancer Drug Targets. 2010;10(2):200–209. doi:10.2174/156800910791054167
   PubMed Web of Science ®Google Scholar
• Cheresh DA, Pierschbacher MD, Herzig MA, Mujoo K. Disialogangliosides GD2 and GD3 are involved in the attachment of human melanoma and neuroblastoma cells to extracellular matrix proteins. J Cell Biol. 1986;102(3):688–696. doi:10.1083/jcb.102.3.688
   Web of Science ®Google Scholar
• Yuki N, Yamada M, Tagawa Y, Takahashi H, Handa S. Pathogenesis of the neurotoxicity caused by anti-GD2 antibody therapy. J Neurol Sci. 1997;149(2):127–130. doi:10.1016/S0022-510X(97)05390-2
   PubMed Web of Science ®Google Scholar
• Sorkin LS, Otto M, Baldwin WM, et al. Anti-GD(2) with an FC point mutation reduces complement fixation and decreases antibody-induced allodynia. Pain. 2010;149(1):135–142. doi:10.1016/j.pain.2010.01.024
   PubMed Web of Science ®Google Scholar
• Baluna R, Vitetta ES. Vascular leak syndrome: a side effect of immunotherapy. Immunopharmacology. 1997;37(2–3):117–132. doi:10.1016/S0162-3109(97)00041-6
   PubMed Web of Science ®Google Scholar
• Matthay KK. Interleukin 2 plus anti-GD2 immunotherapy: helpful or harmful? Lancet Oncol. 2018;19(12):1549–1551. doi:10.1016/S1470-2045(18)30627-2
   PubMed Web of Science ®Google Scholar
• Kushner BH, Cheung NK. GM-CSF enhances 3F8 monoclonal antibody-dependent cellular cytotoxicity against human melanoma and neuroblastoma. Blood. 1989;73(7):1936–1941. doi:10.1182/blood.V73.7.1936.1936
   PubMed Web of Science ®Google Scholar
• Cheung NK, Kushner BH, Cheung IY, et al. Anti-G(D2) antibody treatment of minimal residual stage 4 neuroblastoma diagnosed at more than 1 year of age. J Clin Oncol. 1998;16(9):3053–3060. doi:10.1200/JCO.1998.16.9.3053
   PubMed Web of Science ®Google Scholar
• Kushner BH, Kramer K, Cheung NK. Phase II trial of the anti-G(D2) monoclonal antibody 3F8 and granulocyte-macrophage colony-stimulating factor for neuroblastoma. J Clin Oncol. 2001;19(22):4189–4194. doi:10.1200/JCO.2001.19.22.4189
   Web of Science ®Google Scholar
• Cheung IY, Hsu K, Cheung NK. Activation of peripheral-blood granulocytes is strongly correlated with patient outcome after immunotherapy with anti-GD2 monoclonal antibody and granulocyte-macrophage colony-stimulating factor. J Clin Oncol. 2012;30(4):426–432. doi:10.1200/JCO.2011.37.6236
   Web of Science ®Google Scholar
• Cheung NK, Modak S. Oral (1–>3),(1–>4)-beta-D-glucan synergizes with antiganglioside GD2 monoclonal antibody 3F8 in the therapy of neuroblastoma. Clin Cancer Res. 2002;8(5):1217–1223.
   PubMed Web of Science ®Google Scholar
• Cheung NK, Kushner BH, Yeh SD, Larson SM. 3F8 monoclonal antibody treatment of patients with stage 4 neuroblastoma: a phase II study. Int J Oncol. 1998;12(6):1299–1306. doi:10.3892/ijo.12.6.1299
   PubMed Web of Science ®Google Scholar
• Johnson E, Dean SM, Sondel PM. Antibody-based immunotherapy in high-risk neuroblastoma. Expert Rev Mol Med. 2007;9(34):1–21. doi:10.1017/S1462399407000518
   Google Scholar
• Cheung NK, Cheung IY, Kramer K, et al. Key role for myeloid cells: phase II results of anti-G(D2) antibody 3F8 plus granulocyte-macrophage colony-stimulating factor for chemoresistant osteomedullary neuroblastoma. Int J Cancer. 2014;135(9):2199–2205.
   PubMed Web of Science ®Google Scholar
• Cheung NK, Cheung IY, Kushner BH, et al. Murine anti-GD2 monoclonal antibody 3F8 combined with granulocyte-macrophage colony-stimulating factor and 13-cis-retinoic acid in high-risk patients with stage 4 neuroblastoma in first remission. J Clin Oncol. 2012;30(26):3264–3270. doi:10.1200/JCO.2011.41.3807
   PubMed Web of Science ®Google Scholar
• Kushner BH, Ostrovnaya I, Cheung IY, et al. Prolonged progression-free survival after consolidating second or later remissions of neuroblastoma with anti-GD2 immunotherapy and isotretinoin: a prospective Phase II study. Oncoimmunology. 2015;4(7):e1016704. doi:10.1080/2162402X.2015.1016704
   PubMed Web of Science ®Google Scholar
• Cheung IY, Kushner BH, Modak S, Basu EM, Roberts SS, Cheung NV. Phase I trial of anti-GD2 monoclonal antibody hu3F8 plus GM-CSF: impact of body weight, immunogenicity and anti-GD2 response on pharmacokinetics and survival. Oncoimmunology. 2017;6(11):e1358331. doi:10.1080/2162402X.2017.1358331
   Web of Science ®Google Scholar
• Handgretinger R, Baader P, Dopfer R, et al. A phase I study of neuroblastoma with the anti-ganglioside GD2 antibody 14.G2a. Cancer Immunol Immunother. 1992;35(3):199–204. doi:10.1007/BF01756188
   PubMed Web of Science ®Google Scholar
• Frost JD, Hank JA, Reaman GH, et al. A phase I/IB trial of murine monoclonal anti-GD2 antibody 14.G2a plus interleukin-2 in children with refractory neuroblastoma: a report of the Children’s Cancer Group. Cancer. 1997;80(2):317–333. doi:10.1002/(SICI)1097-0142(19970715)80:2<317::AID-CNCR21>3.0.CO;2-W
   PubMed Web of Science ®Google Scholar
• Cheung NK, Cheung IY, Canete A, et al. Antibody response to murine anti-GD2 monoclonal antibodies: correlation with patient survival. Cancer Res. 1994;54(8):2228–2233.
   PubMed Web of Science ®Google Scholar
• Lu RM, Hwang YC, Liu IJ, et al. Development of therapeutic antibodies for the treatment of diseases. J Biomed Sci. 2020;27(1):1.
   PubMed Web of Science ®Google Scholar
• Mueller BM, Romerdahl CA, Gillies SD, Reisfeld RA. Enhancement of antibody-dependent cytotoxicity with a chimeric anti-GD2 antibody. J Immunol. 1990;144(4):1382–1386.
   PubMed Web of Science ®Google Scholar
• Handgretinger R, Anderson K, Lang P, et al. A phase I study of human/mouse chimeric antiganglioside GD2 antibody ch14.18 in patients with neuroblastoma. EurJ Cancer. 1995;31(2):261–267. doi:10.1016/0959-8049(94)00413-Y
   Web of Science ®Google Scholar
• Yu AL, Uttenreuther-Fischer MM, Huang CS, et al. Phase I trial of a human-mouse chimeric anti-disialoganglioside monoclonal antibody ch14.18 in patients with refractory neuroblastoma and osteosarcoma. J Clin Oncol. 1998;16(6):2169–2180. doi:10.1200/JCO.1998.16.6.2169
   PubMed Web of Science ®Google Scholar
• Murray JL, Kleinerman ES, Jia SF, et al. Phase Ia/Ib trial of anti-GD2 chimeric monoclonal antibody 14.18 (ch14.18) and recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) in metastatic melanoma. J Immunother Emphasis Tumor Immunol. 1996;19(3):206–217. doi:10.1097/00002371-199605000-00005
   Web of Science ®Google Scholar
• Saleh MN, Khazaeli MB, Wheeler RH, et al. Phase I trial of the chimeric anti-GD2 monoclonal antibody ch14.18 in patients with malignant melanoma. Hum Antibodies Hybridomas. 1992;3(1):19–24. doi:10.3233/HAB-1992-3104
   Google Scholar
• Albertini MR, Gan J, Jaeger P, et al. Systemic interleukin-2 modulates the anti-idiotypic response to chimeric anti-GD2 antibody in patients with melanoma. J Immunother Emphasis Tumor Immunol. 1996;19(4):278–295.
   PubMed Web of Science ®Google Scholar
• Albertini MR, Hank JA, Schiller JH, et al. Phase IB trial of chimeric antidisialoganglioside antibody plus interleukin 2 for melanoma patients. Clin Cancer Res. 1997;3(8):1277–1288.
   PubMed Web of Science ®Google Scholar
• Yu AL, Batova A, Alvarado C, et al. Usefulness of a chimeric anti-GD2 (ch14.18) and GM-CSF for refractory neuroblastoma: a POG phase II study. PROC ASCO. 1997;16:1846.
   Google Scholar
• Ozkaynak MF, Sondel PM, Krailo MD, et al. Phase I study of chimeric human/murine anti-ganglioside G(D2) monoclonal antibody (ch14.18) with granulocyte-macrophage colony-stimulating factor in children with neuroblastoma immediately after hematopoietic stem-cell transplantation: a Children’s Cancer Group Study. J Clin Oncol. 2000;18(24):4077–4085. doi:10.1200/JCO.2000.18.24.4077
   PubMed Web of Science ®Google Scholar
• Simon T, Hero B, Faldum A, et al. Consolidation treatment with chimeric anti-GD2-antibody ch14.18 in children older than 1 year with metastatic neuroblastoma. J Clin Oncol. 2004;22(17):3549–3557. doi:10.1200/JCO.2004.08.143
   PubMed Web of Science ®Google Scholar
• Gilman AL, Ozkaynak MF, Matthay KK, et al. Phase I study of ch14.18 with granulocyte-macrophage colony-stimulating factor and interleukin-2 in children with neuroblastoma after autologous bone marrow transplantation or stem-cell rescue: a report from the Children’s Oncology Group. J Clin Oncol. 2009;27(1):85–91. doi:10.1200/JCO.2006.10.3564
   PubMed Web of Science ®Google Scholar
• Mody R, Naranjo A, Van Ryn C, et al. Irinotecan-temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, Phase 2 trial. Lancet Oncol. 2017;18(7):946–957. doi:10.1016/S1470-2045(17)30355-8
   PubMed Web of Science ®Google Scholar
• Mody R, Yu AL, Naranjo A, et al. Irinotecan, temozolomide, and dinutuximab with GM-CSF in children with refractory or relapsed neuroblastoma: a report from the Children’s Oncology Group. J Clin Oncol. 2020;38(19):2160–2169. doi:10.1200/JCO.20.00203
   PubMed Web of Science ®Google Scholar
• EMA approval of dinutuximab beta; 2020. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/qarziba. Accessed September 10, 2020.
   Google Scholar
• Ladenstein R, Weixler S, Baykan B, et al. Ch14.18 antibody produced in CHO cells in relapsed or refractory Stage 4 neuroblastoma patients: a SIOPEN Phase 1 study. mAbs. 2013;5(5):801–809. doi:10.4161/mabs.25215
   PubMed Web of Science ®Google Scholar
• Ladenstein R, Potschger U, Valteau-Couanet D, et al. Investigation of the role of dinutuximab beta-based immunotherapy in the SIOPEN high-risk neuroblastoma 1 trial (HR-NBL1). Cancers. 2020;12(2):309. doi:10.3390/cancers12020309
   Web of Science ®Google Scholar
• Ladenstein R, Potschger U, Valteau-Couanet D, et al. Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN): a multicentre, randomised, phase 3 trial. Lancet Oncol. 2018;19(12):1617–1629. doi:10.1016/S1470-2045(18)30578-3
   PubMed Web of Science ®Google Scholar
• Mueller I, Ehlert K, Endres S, et al. Tolerability, response and outcome of high-risk neuroblastoma patients treated with long-term infusion of anti-GD2 antibody ch14.18/CHO. mAbs. 2018;10(1):55–61. doi:10.1080/19420862.2017.1402997
   PubMed Web of Science ®Google Scholar
• Harding FA, Stickler MM, Razo J, DuBridge RB. The immunogenicity of humanized and fully human antibodies: residual immunogenicity resides in the CDR regions. mAbs. 2010;2(3):256–265. doi:10.4161/mabs.2.3.11641
   PubMed Web of Science ®Google Scholar
• Thommesen JE, Michaelsen TE, Loset GA, Sandlie I, Brekke OH. Lysine 322 in the human IgG3 C(H)2 domain is crucial for antibody dependent complement activation. MolImmunol. 2000;37(16):995–1004.
   Google Scholar
• Navid F, Sondel PM, Barfield R, et al. Phase I trial of a novel anti-GD2 monoclonal antibody, Hu14.18K322A, designed to decrease toxicity in children with refractory or recurrent neuroblastoma. J Clin Oncol. 2014;32(14):1445–1452. doi:10.1200/JCO.2013.50.4423
   PubMed Web of Science ®Google Scholar
• Anghelescu DL, Goldberg JL, Faughnan LG, et al. Comparison of pain outcomes between two anti-GD2 antibodies in patients with neuroblastoma. Pediatr Blood Cancer. 2015;62(2):224–228. doi:10.1002/pbc.25280
   PubMed Web of Science ®Google Scholar
• Furman WL, Federico SM, McCarville MB, et al. A phase II Trial of Hu14.18K322A in combination with induction chemotherapy in children with newly diagnosed high-risk neuroblastoma. Clin Cancer Res. 2019;25(21):6320–6328. doi:10.1158/1078-0432.CCR-19-1452
   PubMed Web of Science ®Google Scholar
• Ady N, Zucker JM, Asselain B, et al. A new 123I-MIBG whole body scan scoring method–application to the prediction of the response of metastases to induction chemotherapy in stage IV neuroblastoma. Eur J Cancer. 1995;31(2):256–261. doi:10.1016/0959-8049(94)00509-4
   Web of Science ®Google Scholar
• Cheung NK, Guo H, Hu J, Tassev DV, Cheung IY. Humanizing murine IgG3 anti-GD2 antibody m3F8 substantially improves antibody-dependent cell-mediated cytotoxicity while retaining targeting in vivo. Oncoimmunology. 2012;1(4):477–486. doi:10.4161/onci.19864
   PubMed Web of Science ®Google Scholar
• Kushner BH, Cheung IY, Modak S, Basu EM, Roberts SS, Cheung NK. Humanized 3F8 Anti-G D2 monoclonal antibody dosing with granulocyte-macrophage colony-stimulating factor in patients with resistant neuroblastoma. JAMA Oncol. 2018;4:1729. doi:10.1001/jamaoncol.2018.4005
   PubMed Web of Science ®Google Scholar
• Wang W, Wang EQ, Balthasar JP. Monoclonal antibody pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther. 2008;84(5):548–558. doi:10.1038/clpt.2008.170
   PubMed Web of Science ®Google Scholar
• Ryman JT, Meibohm B. Pharmacokinetics of monoclonal antibodies. CPT Pharmacometr Syst Pharmacol. 2017;6(9):576–588. doi:10.1002/psp4.12224
   PubMedGoogle Scholar
• Dostalek M, Gardner I, Gurbaxani BM, Rose RH, Chetty M. Pharmacokinetics, pharmacodynamics and physiologically-based pharmacokinetic modelling of monoclonal antibodies. Clin Pharmacokinet. 2013;52(2):83–124.
   PubMed Web of Science ®Google Scholar
• Deng R, Jin F, Prabhu S, Iyer S. Monoclonal antibodies: what are the pharmacokinetic and pharmacodynamic considerations for drug development? Expert Opin Drug Metab Toxicol. 2012;8(2):141–160. doi:10.1517/17425255.2012.643868
   PubMed Web of Science ®Google Scholar
• Lobo ED, Hansen RJ, Balthasar JP. Antibody pharmacokinetics and pharmacodynamics. J Pharm Sci. 2004;93(11):2645–2668. doi:10.1002/jps.20178
   PubMed Web of Science ®Google Scholar
• Siebert N, Eger C, Seidel D, et al. Pharmacokinetics and pharmacodynamics of ch14.18/CHO in relapsed/refractory high-risk neuroblastoma patients treated by long-term infusion in combination with IL-2. mAbs. 2016.
   Web of Science ®Google Scholar
• Ladenstein RL, Poetschger U, Valteau-Couanet D, et al. Randomization of dose-reduced subcutaneous interleukin-2 (scIL2) in maintenance immunotherapy (IT) with anti-GD2 antibody dinutuximab beta (DB) long-term infusion (LTI) in front line high-risk neuroblastoma patients: early results from the HR-NBL1/SIOPEN trial. J Clin Oncol. 2019;37(15).
   Web of Science ®Google Scholar
• Desai AV, Fox E, Smith LM, Lim AP, Maris JM, Balis FM. Pharmacokinetics of the chimeric anti-GD2 antibody, ch14.18, in children with high-risk neuroblastoma. Cancer Chemother Pharmacol. 2014;74(5):1047–1055. doi:10.1007/s00280-014-2575-9
   PubMed Web of Science ®Google Scholar
• Yeh SD, Larson SM, Burch L, et al. Radioimmunodetection of neuroblastoma with iodine-131-3F8: correlation with biopsy, iodine-131-metaiodobenzylguanidine and standard diagnostic modalities. J Nucl Med. 1991;32(5):769–776.
   Web of Science ®Google Scholar
• Reuland P, Geiger L, Thelen MH, et al. Follow-up in neuroblastoma: comparison of metaiodobenzylguanidine and a chimeric anti-GD2 antibody for detection of tumor relapse and therapy response. J Pediatr Hematol Oncol. 2001;23(7):437–442. doi:10.1097/00043426-200110000-00009
   PubMed Web of Science ®Google Scholar
• Vavere AL, Butch ER, Dearling JL, et al. 64Cu-p-NH2-Bn-DOTA-hu14.18K322A, a PET radiotracer targeting neuroblastoma and melanoma. J Nucl Med. 2012;53(11):1772–1778. doi:10.2967/jnumed.112.104208
   Web of Science ®Google Scholar
• Modak S, Cheung NK. Antibody-based targeted radiation to pediatric tumors. J Nucl Med. 2005;46(Suppl 1):157S–163S.
   PubMed Web of Science ®Google Scholar
• Cheung NK, Kushner BH, LaQuaglia M, et al. N7: a novel multi-modality therapy of high risk neuroblastoma (NB) in children diagnosed over 1 year of age. Med Pediatr Oncol. 2001;36(1):227–230. doi:10.1002/1096-911X(20010101)36:1<227::AID-MPO1055>3.0.CO;2-U
   PubMedGoogle Scholar
• Sondel PM, Hank JA. Combination therapy with interleukin-2 and antitumor monoclonal antibodies. Cancer J Sci Am. 1997;3(Suppl 1):S121–127.
   Google Scholar
• Nguyen R, Houston J, Chan WK, Finkelstein D, Dyer MA. The role of interleukin-2, all-trans retinoic acid, and natural killer cells: surveillance mechanisms in anti-GD2 antibody therapy in neuroblastoma. Cancer Immunol Immunother. 2018;67(4):615–626. doi:10.1007/s00262-017-2108-6
   Web of Science ®Google Scholar
• Ribeiro RC, Rill D, Roberson PK, et al. Continuous infusion of interleukin-2 in children with refractory malignancies. Cancer. 1993;72(2):623–628. doi:10.1002/1097-0142(19930715)72:2<623::AID-CNCR2820720248>3.0.CO;2-S
   Web of Science ®Google Scholar
• Yang RK, Kalogriopoulos NA, Rakhmilevich AL, et al. Intratumoral hu14.18-IL-2 (IC) induces local and systemic antitumor effects that involve both activated T and NK cells as well as enhanced IC retention. J Immunol. 2012;189(5):2656–2664. doi:10.4049/jimmunol.1200934
   PubMed Web of Science ®Google Scholar
• Yamane BH, Hank JA, Albertini MR, Sondel PM. The development of antibody-IL-2 based immunotherapy with hu14.18-IL2 (EMD-273063) in melanoma and neuroblastoma. Expert Opin Investig Drugs. 2009;18(7):991–1000. doi:10.1517/13543780903048911
   PubMed Web of Science ®Google Scholar
• Osenga KL, Hank JA, Albertini MR, et al. A phase I clinical trial of the hu14.18-IL2 (EMD 273063) as a treatment for children with refractory or recurrent neuroblastoma and melanoma: a study of the Children’s Oncology Group. Clin Cancer Res. 2006;12(6):1750–1759. doi:10.1158/1078-0432.CCR-05-2000
   PubMed Web of Science ®Google Scholar
• Shusterman S, London WB, Gillies SD, et al. Antitumor activity of hu14.18-IL2 in patients with relapsed/refractory neuroblastoma: a Children’s Oncology Group (COG) phase II study. J Clin Oncol. 2010;28(33):4969–4975. doi:10.1200/JCO.2009.27.8861
   PubMed Web of Science ®Google Scholar
• Alvarez-Rueda N, Desselle A, Cochonneau D, et al. A monoclonal antibody to O-acetyl-GD2 ganglioside and not to GD2 shows potent anti-tumor activity without peripheral nervous system cross-reactivity. PLoS One. 2011;6(9):e25220. doi:10.1371/journal.pone.0025220
   PubMed Web of Science ®Google Scholar
• Terme M, Dorvillius M, Cochonneau D, et al. Chimeric antibody c.8B6 to O-acetyl-GD2 mediates the same efficient anti-neuroblastoma effects as therapeutic ch14.18 antibody to GD2 without antibody induced allodynia. PLoS One. 2014;9(2):e87210. doi:10.1371/journal.pone.0087210
   PubMed Web of Science ®Google Scholar
• Fleurence J, Fougeray S, Bahri M, et al. Targeting O-Acetyl-GD2 ganglioside for cancer immunotherapy. J Immunol Res. 2017;2017:5604891. doi:10.1155/2017/5604891
   PubMed Web of Science ®Google Scholar
• Castriconi R, Dondero A, Augugliaro R, et al. Identification of 4Ig-B7-H3 as a neuroblastoma-associated molecule that exerts a protective role from an NK cell-mediated lysis. Proc Natl Acad Sci U S A. 2004;101(34):12640–12645. doi:10.1073/pnas.0405025101
   PubMed Web of Science ®Google Scholar
• Gregorio A, Corrias MV, Castriconi R, et al. Small round blue cell tumours: diagnostic and prognostic usefulness of the expression of B7-H3 surface molecule. Histopathology. 2008;53(1):73–80. doi:10.1111/j.1365-2559.2008.03070.x
   PubMed Web of Science ®Google Scholar
• Picarda E, Ohaegbulam KC, Zang X. Molecular pathways: targeting B7-H3 (CD276) for human cancer immunotherapy. Clin Cancer Res. 2016;22(14):3425–3431. doi:10.1158/1078-0432.CCR-15-2428
   PubMed Web of Science ®Google Scholar
• Du H, Hirabayashi K, Ahn S, et al. Antitumor responses in the absence of toxicity in solid tumors by targeting B7-H3 via chimeric antigen receptor T cells. Cancer Cell. 2019;35(2):221–237 e228. doi:10.1016/j.ccell.2019.01.002
   PubMed Web of Science ®Google Scholar
• Modak S, Kramer K, Gultekin SH, Guo HF, Cheung NK. Monoclonal antibody 8H9 targets a novel cell surface antigen expressed by a wide spectrum of human solid tumors. Cancer Res. 2001;61(10):4048–4054.
   PubMed Web of Science ®Google Scholar
• Ahmed M, Cheng M, Zhao Q, et al. Humanized affinity-matured monoclonal antibody 8H9 has potent antitumor activity and binds to FG loop of tumor antigen B7-H3. J Biol Chem. 2015;290(50):30018–30029. doi:10.1074/jbc.M115.679852
   PubMed Web of Science ®Google Scholar
• Kramer K, Kushner B, Modak S, et al. A curative approach to central nervous system metastases of neuroblastoma. Pediatr Blood Cancer. 2019;66:S56–S56.
   Web of Science ®Google Scholar
• Kramer K, Kushner BH, Modak S, et al. A curative approach to central nervous system metastases of neuroblastoma. J Clin Oncol. 2017;35:10545. doi:10.1200/JCO.2017.35.15_suppl.10545
   Web of Science ®Google Scholar
• Desantes K, Maris JM, McDowell K, et al. A phase 1, open-label, dose escalation study of enoblituzumab (MGA271) in pediatric patients with B7-H3-expressing relapsed or refractory solid tumors. J Clin Oncol. 2017;35:TPS2596–TPS2596. doi:10.1200/JCO.2017.35.15_suppl.TPS2596
   Web of Science ®Google Scholar
• Bresler SC, Weiser DA, Huwe PJ, et al. ALK mutations confer differential oncogenic activation and sensitivity to ALK inhibition therapy in neuroblastoma. Cancer Cell. 2014;26(5):682–694. doi:10.1016/j.ccell.2014.09.019
   PubMed Web of Science ®Google Scholar
• Carpenter EL, Haglund EA, Mace EM, et al. Antibody targeting of anaplastic lymphoma kinase induces cytotoxicity of human neuroblastoma. Oncogene. 2012;31(46):4859–4867. doi:10.1038/onc.2011.647
   Web of Science ®Google Scholar
• Dondero A, Pastorino F, Della Chiesa M, et al. PD-L1 expression in metastatic neuroblastoma as an additional mechanism for limiting immune surveillance. Oncoimmunology. 2016;5(1):e1064578. doi:10.1080/2162402X.2015.1064578
   PubMed Web of Science ®Google Scholar
• Siebert N, Zumpe M, Juttner M, Troschke-Meurer S, Lode HN. PD-1 blockade augments anti-neuroblastoma immune response induced by anti-GD2 antibody ch14.18/CHO. Oncoimmunology. 2017;6(10):e1343775. doi:10.1080/2162402X.2017.1343775
   Web of Science ®Google Scholar
• Ehlert K, Hansjuergens I, Zinke A, et al. Nivolumab and dinutuximab beta in two patients with refractory neuroblastoma. J Immunother Cancer. 2020;8(1):e000540. doi:10.1136/jitc-2020-000540
   Web of Science ®Google Scholar
• Li N, Gao W, Zhang YF, Ho M. Glypicans as cancer therapeutic targets. Trends Cancer. 2018;4(11):741–754. doi:10.1016/j.trecan.2018.09.004
   PubMed Web of Science ®Google Scholar
• Bosse KR, Raman P, Zhu Z, et al. Identification of GPC2 as an oncoprotein and candidate immunotherapeutic target in high-risk neuroblastoma. Cancer Cell. 2017;32(3):295–309 e212. doi:10.1016/j.ccell.2017.08.003
   PubMed Web of Science ®Google Scholar
• Theocharopoulos C, Lialios PP, Gogas H, Ziogas DC. An overview of antibody-drug conjugates in oncological practice. Ther Adv Med Oncol. 2020;12:1758835920962997. doi:10.1177/1758835920962997
   Web of Science ®Google Scholar
• Zhang W, Huang Q, Xiao W, et al. Advances in anti-tumor treatments targeting the CD47/SIRPalpha axis. Front Immunol. 2020;11:18. doi:10.3389/fimmu.2020.00018
   PubMed Web of Science ®Google Scholar
• Aktas S, Ozdemir A, Serinan E, Altun Z, Olgun N. “Don’t Eat Me” signals of neuroblastoma by CD47 for immune escape: a novel prognostic biomarker. Proceedings. 2018;2(25):1538. doi:10.3390/proceedings2251538
   Google Scholar
• Oronsky B, Carter C, Reid T, Brinkhaus F, Knox SJ. Just eat it: a review of CD47 and SIRP-alpha antagonism. Semin Oncol. 2020;47(2–3):117–124. doi:10.1053/j.seminoncol.2020.05.009
   PubMed Web of Science ®Google Scholar
• Jaiswal S, Jamieson CH, Pang WW, et al. CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis. Cell. 2009;138(2):271–285. doi:10.1016/j.cell.2009.05.046
   PubMed Web of Science ®Google Scholar
• Asgharzadeh S, Salo JA, Ji L, et al. Clinical significance of tumor-associated inflammatory cells in metastatic neuroblastoma. J Clin Oncol. 2012;30(28):3525–3532. doi:10.1200/JCO.2011.40.9169
   PubMed Web of Science ®Google Scholar
• Theruvath J, Smith B, Linde MH, et al. Abstract PR07: GD2 is a macrophage checkpoint molecule and combined GD2/CD47 blockade results in synergistic effects and tumor clearance in xenograft models of neuroblastoma and osteosarcoma. Cancer Res. 2020;80(14Supplement):PR07.
   Google Scholar
• Labrijn AF, Janmaat ML, Reichert JM, Parren P. Bispecific antibodies: a mechanistic review of the pipeline. Nat Rev Drug Discov. 2019;18(8):585–608. doi:10.1038/s41573-019-0028-1
   PubMed Web of Science ®Google Scholar
• Yankelevich M, Kondadasula SV, Thakur A, Buck S, Cheung NK, Lum LG. Anti-CD3 x anti-GD2 bispecific antibody redirects T-cell cytolytic activity to neuroblastoma targets. Pediatr Blood Cancer. 2012;59(7):1198–1205. doi:10.1002/pbc.24237
   PubMed Web of Science ®Google Scholar
• Hernandez R, Erbe A, Gerhardt D, et al. GD2/B7-H3 bispecific antibodies for next-generation neuroblastoma treatment</strong>. J Nucl Med. 2020;61(supplement1):376.
   Google Scholar
• Erbe A, Gerhardt D, Hernandez R, et al. Improving specific targeting of tumors through bispecific sniper antibodies. J Immunother Cancer. 2020;8:A280–A280. doi:10.1136/jitc-2020-SITC2020.0461
   Web of Science ®Google Scholar
• Mori K, Iida S, Yamane-Ohnuki N, et al. Non-fucosylated therapeutic antibodies: the next generation of therapeutic antibodies. Cytotechnology. 2007;55(2–3):109–114. doi:10.1007/s10616-007-9103-2
   PubMed Web of Science ®Google Scholar
• Shields RL, Lai J, Keck R, et al. Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity. J Biol Chem. 2002;277(30):26733–26740. doi:10.1074/jbc.M202069200
   PubMed Web of Science ®Google Scholar
• Hank JA, Robinson RR, Surfus J, et al. Augmentation of antibody dependent cell mediated cytotoxicity following in vivo therapy with recombinant interleukin 2. Cancer Res. 1990;50(17):5234–5239.
   PubMed Web of Science ®Google Scholar
• Tanaka A, Sakaguchi S. Regulatory T cells in cancer immunotherapy. Cell Res. 2017;27(1):109–118. doi:10.1038/cr.2016.151
   PubMed Web of Science ®Google Scholar
• Lode H, Siebert N, Troschke-Meurer S, et al. Administration of subcutaneous IL-2 is associated with strong induction of regulatory T cells in high-risk neuroblastoma patients treated with dinutuximab beta, a SIOPEN study. Pediatr Blood Cancer. 2019;66:S55–S56.
   Web of Science ®Google Scholar
• Nguyen R, Moustaki A, Norrie JL, et al. Interleukin-15 enhances anti-GD2 antibody-mediated cytotoxicity in an orthotopic PDX model of neuroblastoma. Clin Cancer Res. 2019;25(24):7554–7564. doi:10.1158/1078-0432.CCR-19-1045
   PubMed Web of Science ®Google Scholar
• Heinze A, Grebe B, Bremm M, et al. The synergistic use of IL-15 and IL-21 for the generation of NK cells from CD3/CD19-depleted grafts improves their ex vivo expansion and cytotoxic potential against neuroblastoma: perspective for optimized immunotherapy post haploidentical stem cell transplantation. Front Immunol. 2019;10. doi:10.3389/fimmu.2019.02816
   Web of Science ®Google Scholar
• Nowak AK, Robinson BW, Lake RA. Synergy between chemotherapy and immunotherapy in the treatment of established murine solid tumors. Cancer Res. 2003;63(15):4490–4496.
   PubMed Web of Science ®Google Scholar
• Lake RA, Robinson BW. Immunotherapy and chemotherapy–a practical partnership. Nat Rev Cancer. 2005;5(5):397–405. doi:10.1038/nrc1613
   PubMed Web of Science ®Google Scholar
• Buhtoiarov IN, Sondel PM, Wigginton JM, et al. Anti-tumour synergy of cytotoxic chemotherapy and anti-CD40 plus CpG-ODN immunotherapy through repolarization of tumour-associated macrophages. Immunology. 2011;132(2):226–239. doi:10.1111/j.1365-2567.2010.03357.x
   Web of Science ®Google Scholar
• Holden SA, Lan Y, Pardo AM, Wesolowski JS, Gillies SD. Augmentation of antitumor activity of an antibody-interleukin 2 immunocytokine with chemotherapeutic agents. Clin Cancer Res. 2001;7(9):2862–2869.
   PubMed Web of Science ®Google Scholar
• Ghiringhelli F, Larmonier N, Schmitt E, et al. CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. Eur J Immunol. 2004;34(2):336–344. doi:10.1002/eji.200324181
   PubMed Web of Science ®Google Scholar
• Menard C, Martin F, Apetoh L, Bouyer F, Ghiringhelli F. Cancer chemotherapy: not only a direct cytotoxic effect, but also an adjuvant for antitumor immunity. Cancer Immunol Immunother. 2008;57(11):1579–1587. doi:10.1007/s00262-008-0505-6
   PubMed Web of Science ®Google Scholar
• Zitvogel L, Apetoh L, Ghiringhelli F, Kroemer G. Immunological aspects of cancer chemotherapy. Nat Rev Immunol. 2008;8(1):59–73. doi:10.1038/nri2216
   PubMed Web of Science ®Google Scholar
• Raffaghello L, Marimpietri D, Pagnan G, et al. Anti-GD2 monoclonal antibody immunotherapy: a promising strategy in the prevention of neuroblastoma relapse. Cancer Lett. 2003;197(1–2):205–209. doi:10.1016/S0304-3835(03)00100-9
   PubMed Web of Science ®Google Scholar
• Nowak AK, Lake RA, Marzo AL, et al. Induction of tumor cell apoptosis in vivo increases tumor antigen cross-presentation, cross-priming rather than cross-tolerizing host tumor-specific CD8 T cells. J Immunol. 2003;170(10):4905–4913. doi:10.4049/jimmunol.170.10.4905
   PubMed Web of Science ®Google Scholar
• Park JA, Cheung NV. Targets and antibody formats for immunotherapy of neuroblastoma. J Clin Oncol. 2020;38(16):1836–1848. doi:10.1200/JCO.19.01410
   PubMed Web of Science ®Google Scholar
• Richards RM, Sotillo E, Majzner RG. CAR T cell therapy for neuroblastoma. Front Immunol. 2018;9:2380. doi:10.3389/fimmu.2018.02380
   PubMed Web of Science ®Google Scholar
• Heczey A, Louis CU. Advances in chimeric antigen receptor immunotherapy for neuroblastoma. Discov Med. 2013;16(90):287–294.
   PubMed Web of Science ®Google Scholar
• Louis CU, Savoldo B, Dotti G, et al. Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. Blood. 2011;118(23):6050–6056. doi:10.1182/blood-2011-05-354449
   PubMed Web of Science ®Google Scholar
• Oh S, Lee JH, Kwack K, Choi SW. Natural killer cell therapy: a new treatment paradigm for solid tumors. Cancers. 2019;11(10):1534. doi:10.3390/cancers11101534
   PubMed Web of Science ®Google Scholar
• Mehta RS, Rezvani K. Chimeric antigen receptor expressing natural killer cells for the immunotherapy of cancer. Front Immunol. 2018;9:283. doi:10.3389/fimmu.2018.00283
   PubMed Web of Science ®Google Scholar
• Modak S, Le Luduec JB, Cheung IY, et al. Adoptive immunotherapy with haploidentical natural killer cells and Anti-GD2 monoclonal antibody m3F8 for resistant neuroblastoma: results of a phase I study. Oncoimmunology. 2018;7(8):e1461305. doi:10.1080/2162402X.2018.1461305
   PubMed Web of Science ®Google Scholar
• Barry WE, Jackson JR, Asuelime GE, et al. Activated natural killer cells in combination with anti-GD2 antibody dinutuximab improve survival of mice after surgical resection of primary neuroblastoma. Clin Cancer Res. 2018;25:325–333. doi:10.1158/1078-0432.CCR-18-1317
   Web of Science ®Google Scholar
• Uttenreuther-Fischer MM, Huang CS, Reisfeld RA, Yu AL. Pharmacokinetics of anti-ganglioside GD2 mAb 14G2a in a phase 1 trial in pediatric cancer patients. Cancer Immunol Immunother. 1995;41:29–36.
   PubMed Web of Science ®Google Scholar
• Kramer K, Cheung NK, Humm JL, et al. Targeted radioimmunotherapy for leptomeningeal cancer using (131)I-3F8. Med Pediatr Oncol. 2000;35:716–8.
   PubMedGoogle Scholar